Clinical Trial Update: Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib, melphalan, and dexamethasone in treating primary systemic amyloidosis and light chain deposition disease has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Deposition Disease
• Systemic Amyloidosis

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Melphalan (Melphalan)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Primary Systemic Amyloidosis, Light Chain Deposition Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-03-30